We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Gut Microbes Could Enable Early Detection and Treatment of Pancreatic Cancer

By LabMedica International staff writers
Posted on 13 Jun 2025

Pancreatic cancer remains one of the most serious and challenging diseases in oncology due to its difficulty in detection and limited treatment options. More...

Now, a new international collaborative study suggests that in the future, early-stage pancreatic cancer could potentially be identified through the analysis of gut microbes. These microbes may also present new opportunities for developing therapies.

In this study, researchers from the University of Jyväskylä (Jyväskylä, Finland) and their collaborators analyzed the gut microbiota of over 180 pancreatic cancer patients from Finland and Iran, along with healthy individuals from the same regions. They discovered consistent microbial patterns associated with pancreatic cancer regardless of the patients' geographic or ethnic backgrounds. Compared to the healthy group, the intestinal microbiota of pancreatic cancer patients contained significantly more facultative pathogens and notably fewer beneficial bacteria. Specifically, a decline was observed in helpful bacteria from the Clostridia class, such as the butyric acid–producing Lachnospiraceae, Butyricicoccaceae, and Ruminococcaceae. In contrast, higher levels of potential pathogens like Enterobacteriaceae, Enterococcaceae, and Fusobacteriaceae were found in the gut flora of those with pancreatic cancer.

Based on these findings, the researchers propose that future investigations should explore whether these beneficial microbes could be developed into a new class of probiotics—live microbial products—that could be used alongside standard chemotherapy. This combination could potentially offer a more precise and effective method for treating pancreatic cancer. At the same time, the researchers stress the importance of conducting additional studies in varied populations to validate these results. Furthermore, they created a statistical model using microbiome data, which may eventually assist in predicting pancreatic cancer. This marks a promising initial step toward achieving earlier diagnosis of the disease.

“The findings on beneficial Clostridia are interesting because it has been shown earlier that ordinary Clostridiales populations effectively mediate anti-canceric immune reactions against solid tumors,” said Satu Pekkala, Senior Lecturer from the Faculty of Sport and Health Sciences, University of Jyväskylä.


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.